Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Protein Peptide Letters

• Publication date

  2004-05-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/0929866043407174PMID 15182223
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening

  2007cited by this paper
• Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5

  2004cited by this paper
• The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

  2003cited by this paper
• Monoclonal antibodies inhibit prion replication and delay the development of prion disease

  2003cited by this paper
• Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.

  2003cited by this paper
• Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

  2003cited by this paper
• Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis

  2003cited by this paper
• Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

  2003cited by this paper
• In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis*

  2003cited by this paper
• Alpha-synuclein oligomerization: a role for lipids?

  2003cited by this paper
• Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

  2003cited by this paper
• Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies.

  2003cited by this paper
• Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

  2003cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.

  2002cited by this paper
• A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.

  2002cited by this paper
• Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells.

  2002cited by this paper
• Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion*

  2002cited by this paper
• alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

  2002cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

  2002cited by this paper
• Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.

  2002cited by this paper
• Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease

  2002cited by this paper
• Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

  2002cited by this paper
• Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

  2002cited by this paper
• Neurodegenerative disease: Amyloid pores from pathogenic mutations

  2002cited by this paper
• Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide.

  2002cited by this paper
• Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling

  2002cited by this paper
• Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability*

  2002cited by this paper
• Immunization delays the onset of prion disease in mice.

  2002cited by this paper
• Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.

  2002cited by this paper
• Dementia and Alzheimer disease incidence: a prospective cohort study.

  2002cited by this paper
• Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease

  2002cited by this paper
• Generation of Aggregated β-Amyloid in the Rat Hippocampus Impairs Synaptic Transmission and Plasticity and Causes Memory Deficits

  2001cited by this paper
• Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

  2001cited by this paper
• Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death

  2001cited by this paper
• Inflammation, autotoxicity and Alzheimer disease.

  2001cited by this paper
• Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

  2001cited by this paper
• Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

  2001cited by this paper
• Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors.

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Neuropathology in mice expressing human alpha-synuclein.

  2000cited by this paper
• Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?

  2000cited by this paper
• Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

  2000cited by this paper
• The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.

  2000cited by this paper
• Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

  2000cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000cited by this paper
• A Drosophila model of Parkinson's disease

  2000cited by this paper
• Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

  2000cited by this paper
• The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

  1999cited by this paper
• Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice.

  1999cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999cited by this paper
• Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons

  1999cited by this paper
• Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice

  1999cited by this paper
• Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.

  1999cited by this paper
• Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

  1999cited by this paper
• Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

  1999cited by this paper
• alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.

  1999cited by this paper
• Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro *

  1999cited by this paper
• Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain*

  1999cited by this paper
• Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

  1999cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• An Ultrastructural Study of Amyloid Intermediates in Aβ1–42 Fibrillogenesis

  1999cited by this paper
• Molecular basis of the neurodegenerative disorders.

  1999cited by this paper
• Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.

  1998cited by this paper
• Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity.

  1998cited by this paper
• Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

  1998cited by this paper
• Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease

  1998cited by this paper
• Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity

  1998cited by this paper
• Neuron loss in APP transgenic mice

  1998cited by this paper
• The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells.

  1998cited by this paper
• Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

  1998cited by this paper
• Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

  1998cited by this paper
• Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments

  1998cited by this paper
• Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease

  1998cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• Enhanced Production and Oligomerization of the 42-residue Amyloid β-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins*

  1997cited by this paper
• Genes and parkinsonism.

  1997cited by this paper
• APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1

  1997cited by this paper
• Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

  1997cited by this paper
• Contribution of somal Lewy bodies to neuronal death.

  1997cited by this paper
• Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

  1997cited by this paper
• Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

  1997cited by this paper
• Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse

  1997cited by this paper
• Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches.

  1997cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice

  1997cited by this paper
• Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.

  1997cited by this paper
• Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

  1996cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Altered neurofilament expression does not contribute to Lewy body formation.

  1996cited by this paper
• Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.

  1996cited by this paper
• Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease*

  1996cited by this paper
• Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1

  1996cited by this paper
• Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

  1996cited by this paper
• Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

  1995cited by this paper
• Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*)

  1995cited by this paper
• Apolipoprotein E genotypes and age of onset in early‐onset familial Alzheimer's disease

  1995cited by this paper

• A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

  2025cites this paper
• Activation of the 20S proteasome as a possible strategy to counteract amylin oligomerization in type 2 diabetes.

  2025cites this paper
• Molecular aspects of cytoprotection by Optineurin during stress and disease.

  2025cites this paper
• Cortical Bone Loss and Fragility in a 2-Month Triple Transgenic Mouse Model of Alzheimer’s Disease

  2025cites this paper
• Residue-level structural information from isotope-edited FTIR spectroscopy reveals distinct molecular structures of different amyloid-β42 oligomers

  2025cites this paper
• Nanomodulators That Target Alzheimer’s Disease: A Review

  2024cites this paper
• Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses

  2024cites this paper
• Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis).

  2024cites this paper
• A brief history of amyloid aggregation simulations

  2024cites this paper
• Lifestyle medicine for healthy cognitive aging: A narrative review

  2024cites this paper
• Paying Homage to Microvessel Remodeling and Small Vessel Disease in Neurodegeneration: Implications for the Development of Late-Onset Alzheimer’s Disease

  2024cites this paper
• Gut microbiota and circadian rhythm in Alzheimer’s disease pathophysiology: a review and hypothesis on their association

  2023cites this paper
• Medicinal (Radio)Chemistry: Building Radiopharmaceuticals for the Future.

  2023cites this paper
• IM-MS and ECD-MS/MS Provide Insight into Modulation of Amyloid Proteins Self-Assembly by Peptides and Small Molecules.

  2023cites this paper
• Proteotoxic stress and the ubiquitin proteasome system

  2023cites this paper
• Phloroglucinol, a clinical-used antispasmodic, inhibits amyloid aggregation and degrades the pre-formed amyloid proteins.

  2022cites this paper
• Current understandings and perspectives of petroleum hydrocarbons in Alzheimer’s disease and Parkinson’s disease: a global concern

  2022cites this paper
• Characterization of Orange Peel Extract and Its Potential Protective Effect against Aluminum Chloride-Induced Alzheimer’s Disease

  2022cites this paper
• Neurodegeneration and neuroinflammation are linked, but independent of alpha‐synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease

  2022cites this paper
• Autophagy-independent cytoprotection by optineurin from toxicity of aggregates formed by mutant huntingtin and mutant ataxin-3.

  2022cites this paper
• A Long Journey into the Investigation of the Structure–Dynamics–Function Paradigm in Proteins through the Activities of the Palermo Biophysics Group

  2022cites this paper
• Quantitative super-resolution imaging of pathological aggregates reveals distinct toxicity profiles in different synucleinopathies

  2022cites this paper
• ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease

  2022cites this paper
• Hypothesis on ontogenesis and pathophysiology of Alzheimer’s disease

  2022cites this paper
• Alzheimer’s disease – the journey of a healthy brain into organ failure

  2022cites this paper
• Blockage of Fc Gamma Receptors Alleviates Neuronal and Microglial Toxicity Induced by Palmitic Acid

  2021cites this paper
• NMDA and AMPA receptors dysregulation in Alzheimer's disease.

  2021cites this paper
• Treatment with sodium butyrate has therapeutic benefits for Machado-Joseph disease through the induction of autophagy

  2021cites this paper
• The role of amyloids in Alzheimer's and Parkinson's diseases.

  2021cites this paper
• Proteotoxicity and Autophagy in Neurodegenerative and Cardiovascular Diseases

  2021cites this paper
• Alleviation of Memory Deficit by Bergenin via the Regulation of Reelin and Nrf-2/NF-κB Pathway in Transgenic Mouse Model

  2021cites this paper
• Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis

  2021cites this paper
• Adlay hull extracts attenuate β-amyloid-induced neurotoxicity and oxidative stress in PC12 cells through antioxidative, anti-inflammatory, and antiapoptotic activities

  2021cites this paper
• A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease.

  2020cites this paper
• Green Tea Seed Isolated Theasaponin E1 Ameliorates AD Promoting Neurotoxic Pathogenesis by Attenuating Aβ Peptide Levels in SweAPP N2a Cells

  2020cites this paper
• Optineurin promotes aggregation of mutant huntingtin and mutant ataxin-3, and reduces cytotoxicity of aggregates

  2020cites this paper
• Neuroprotective Effects of Baicalein, Wogonin, and Oroxylin A on Amyloid Beta-Induced Toxicity via NF-κB/MAPK Pathway Modulation

  2020cites this paper
• A lowly populated, transient β-sheet structure in monomeric Aβ1-42 identified by multinuclear NMR of chemical denaturation.

  2020cites this paper
• Neurodegeneration and neuroinflammation are linked, but independent of α-synuclein inclusions, in a seeding/spreading mouse model of Parkinson’s disease

  2020cites this paper
• Disease‐modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil

  2020cites this paper
• Mechanisms of neurodegeneration - Insights from familial Alzheimer's disease.

  2020cites this paper
• Is there a link between inorganic polyphosphate (polyP), mitochondria, and neurodegeneration?

  2020cites this paper
• The Na+/Ca2+exchanger in Alzheimer's disease.

  2020cites this paper
• Distance disintegration delineates the brain connectivity failure of Alzheimer's disease.

  2019cites this paper
• Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression

  2019cites this paper
• Mitochondrial Cholesterol in Alzheimer's Disease and Niemann–Pick Type C Disease

  2019cites this paper
• Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer’s Disease Status and Risk Genotype

  2019cites this paper
• Amyloid β oligomers inhibit growth of human cancer cells

  2019cites this paper
• Mathematical models for brain diseases: formation of senile plaques and neurofibrillary tangles in alzheimer's disease. Modelos matemáticos de enfermedades cerebrales:formación de placas seniles y ovillos neurofibrilares en la enfermedad de alzheimer

  2019cites this paper
• The mechanism of action of clioquinol for the treatment of Alzheimer's disease

  2018influential citation
• Dissociating Alzheimer’S Disease from Amnestic Mild Cognitive Impairment using Time-Frequency Based Eeg Neurometrics

  2018cites this paper
• Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer’s Disease?

  2018cites this paper
• The effect of phloretin on synaptic proteins and adult hippocampal neurogenesis in Aβ (1‐42)‐injected male Wistar rats

  2018cites this paper
• Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity.

  2018cites this paper
• Effets de l’administration de tétrahydrobioptérine en condition physiologique et pathologique : De la neurobiologie au comportement

  2018cites this paper
• Role of ubiquitin-specific protease 25 in the pathogenesis of Alzheimer's disease in Down syndrome

  2018cites this paper
• Antiamyloidogenic Chemical/Biochemical-Based Designed Nanoparticle as Artificial Chaperone for Efficient Inhibition of Protein Aggregation.

  2018cites this paper
• A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers

  2018cites this paper
• Deciphering the Biochemical Pathway and Pharmacokinetic Study of Amyloid βeta-42 with Superparamagnetic Iron Oxide Nanoparticles (SPIONs) Using Systems Biology Approach

  2018cites this paper
• Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex

  2018cites this paper
• Neuro-pathological Implications of β-Amyloid Protein: An Update

  2018cites this paper
• Sideritis scardica extracts inhibit aggregation and toxicity of amyloid-β in Caenorhabditis elegans used as a model for Alzheimer’s disease

  2018cites this paper
• Yeast as a model to study protein misfolding in aged cells.

  2018cites this paper
• Analyzing the Behavior of Neuronal Pathways in Alzheimer's Disease Using Petri Net Modeling Approach

  2018cites this paper
• Effect of fibrillation conditions on the anti-amyloidogenic properties of polyphenols and their involved mechanisms.

  2018cites this paper
• NMR ANALYSIS OF INTRACELLULAR AMYLOID-BETA PEPTIDE

  2017cites this paper
• Neuropathology of Feline Dementia

  2017cites this paper
• A novel DSC approach for evaluating protectant drugs efficacy against dementia.

  2017cites this paper
• Effects of M2000 (D-Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer’s Disease

  2017cites this paper
• Serious Games for Dementia

  2017cites this paper
• Low-temperature exothermic transitions in brain proteome of mice, effect of scopolamine

  2017cites this paper
• Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease

  2017cites this paper
• Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: Is Aβ a Crucial Factor in Both Pathologies?

  2017cites this paper
• Methylene Blue (Tetramethylthionine Chloride) Influences the Mobility of Adult Neural Stem Cells: A Potentially Novel Therapeutic Mechanism of a Therapeutic Approach in the Treatment of Alzheimer’s Disease

  2017cites this paper
• Compilation and Analysis of Enzymes, Engineered Antibodies, and Nanoparticles Designed to Interfere with Amyloid‐β Aggregation

  2017cites this paper
• From redox proteomics to clinical practice : search for therapeutic targets

  2017cites this paper
• Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.

  2017cites this paper
• Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex

  2017cites this paper
• Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain

  2017cites this paper
• Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate

  2017cites this paper
• The protection of novel 2-arylethenylquinoline derivatives against impairment of associative learning memory induced by neural Aβ in C. elegans Alzheimer’s disease model

  2017cites this paper
• Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer’s disease mice

  2017cites this paper
• Kinetics of Protein Aggregates Disposal by Aggrephagy.

  2017cites this paper
• SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.

  2017cites this paper
• Canine and Feline Dementia

  2017cites this paper
• AMYLOD BETAPEPTIDE PROTOFIBRLS AND USES THEREOF

  2017cites this paper
• Apolipoprotein E Related Co-Morbidities and Alzheimer's Disease.

  2016cites this paper
• Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.

  2016cites this paper
• Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.

  2016cites this paper
• Potential mechanisms and implications for the formation of tau oligomeric strains

  2016cites this paper
• Role of Epigenetics in Stem Cell Proliferation and Differentiation: Implications for Treating Neurodegenerative Diseases

  2016cites this paper
• Amyloid fibrillogenesis of lysozyme is suppressed by a food additive brilliant blue FCF.

  2016cites this paper
• Mecanismo de acción de la molécula ácido 2-hidroxi-docosahexaenoico en el tratamiento de la Enfermedad del Alzheimer: Identificación de potenciales receptores en el cerebro

  2016cites this paper
• Polymer-Encapsulated Aβ Peptide Fragments as an Oligomeric-Specific Vaccine for Alzheimer's Disease.

  2016cites this paper
• In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain

  2016cites this paper
• Therapeutic Targeting of Aβ42

  2016cites this paper
• Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer’s Drug Discovery

  2016cites this paper
• Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation.

  2016cites this paper
• Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.

  2016cites this paper
• Substance P and Alzheimer's Disease: Emerging Novel Roles.

  2016cites this paper